국소분절사구체경화증(FSGS) 시장 : 세계 예측(2026-2032년)

The Focal Segmental Glomerulosclerosis Market is projected to grow by USD 3.69 billion at a CAGR of 8.13% by 2032.

Focal segmental glomerulosclerosis (FSGS) is a clinicopathologic kidney disorder characterized by scarring in some glomeruli and only parts of affected glomerular tufts, often presenting with proteinuria, nephrotic syndrome, reduced estimated glomerular filtration rate, edema, and elevated risk of chronic kidney disease progression. The condition includes primary, genetic, secondary, and undetermined forms, making accurate diagnosis and classification essential for treatment planning. Kidney biopsy remains central to confirming FSGS lesions, while genetic testing, immunologic assessment, and longitudinal proteinuria monitoring increasingly support differential diagnosis and risk stratification. The FSGS landscape is gaining attention because unmet clinical needs remain substantial: many patients do not achieve durable proteinuria remission, corticosteroid and immunosuppressive exposure can be clinically burdensome, and recurrence after kidney transplantation is a recognized challenge, particularly in primary disease. Relevant industry themes include FSGS treatment, nephrotic syndrome management, rare kidney disease diagnostics, podocyte injury, proteinuria reduction, chronic kidney disease care pathways, kidney biopsy, genetic kidney disease, APOL1-mediated kidney disease, and precision nephrology.

Transformative Shifts in the FSGS Landscape

The FSGS landscape is being reshaped by a shift from symptom-centered management toward mechanism-informed and precision-oriented care. Historically, treatment relied heavily on supportive therapy, renin-angiotensin-aldosterone system inhibition, blood pressure control, lipid management, edema control, and selective use of corticosteroids or calcineurin inhibitors. Current clinical practice is increasingly differentiating primary FSGS from secondary adaptive forms linked to obesity, reduced nephron mass, reflux nephropathy, hypertension, sickle cell disease, viral infections, medications, and high-risk genetic variants. This distinction is transformative because immunosuppression is not appropriate for every FSGS presentation and may expose patients to avoidable toxicity when the underlying driver is secondary or genetic. Advances in nephropathology, electron microscopy interpretation, podocyte biology, APOL1 risk variant research, and biomarker development are strengthening disease characterization. In parallel, patient registries, rare disease trial networks, and proteinuria-based clinical endpoints are improving evidence generation. The broader trend is clear: FSGS care is moving toward earlier detection, validated subtype classification, kidney-protective supportive therapy, targeted clinical trial enrollment, and multidisciplinary long-term monitoring.

Cumulative Impact of Artificial Intelligence in FSGS

Artificial intelligence is beginning to influence the FSGS ecosystem through digital pathology, clinical decision support, imaging analysis, electronic health record phenotyping, and research acceleration. AI-enabled pathology tools can support quantitative assessment of glomerulosclerosis, interstitial fibrosis, tubular atrophy, and podocyte-related structural changes, helping reduce interobserver variability when paired with expert renal pathology review. Machine learning applied to longitudinal clinical data may assist in identifying patients at higher risk of rapid kidney function decline by integrating proteinuria trajectories, serum creatinine trends, blood pressure, biopsy findings, medication exposure, comorbidities, and genetic information. In drug development and translational nephrology, AI can help mine omics datasets, identify pathway signals, optimize patient stratification, and improve trial feasibility in rare kidney disease populations. However, the cumulative impact depends on rigorous validation, representative datasets, privacy-preserving data governance, transparent algorithms, and integration into clinician-led workflows. AI should be viewed as an augmenting capability rather than a diagnostic replacement, particularly because FSGS is a histologic pattern with diverse causes requiring clinical-pathologic correlation.

Key Regional Insights Across the FSGS Ecosystem

In Asia-Pacific, FSGS priorities are shaped by large chronic kidney disease burdens, expanding nephrology capacity, variable biopsy access, and growing interest in genetic kidney disease evaluation across China, India, Japan, South Korea, and Australia. APOL1-associated FSGS is less central in most Asian populations than in populations with recent African ancestry, but secondary FSGS related to metabolic disease, hypertension, and reduced nephron reserve remains clinically important. North America has strong rare kidney disease research infrastructure, advanced transplant programs, broader access to genetic testing, and high clinical trial participation, with particular attention to APOL1-mediated kidney disease in people of African ancestry and recurrence risk after transplantation. Latin America faces a dual challenge of increasing chronic kidney disease prevalence and uneven access to renal biopsy, immunosuppressive monitoring, and specialist nephrology services, while regional centers in Brazil and Mexico support growing expertise in glomerular disease care. Europe benefits from established nephrology guidelines, cross-border research collaboration, kidney registries, and structured rare disease frameworks that help standardize diagnosis and long-term follow-up. In the Middle East, FSGS management is influenced by high rates of diabetes, obesity, consanguinity-related hereditary kidney disorders, and expanding tertiary nephrology services, especially in Gulf health systems. Across Africa, access to kidney biopsy, genetic testing, dialysis, and transplantation remains uneven, yet the region is highly relevant to FSGS research because APOL1 high-risk genotypes are present in several populations with West African ancestry and are associated with increased risk of FSGS and other kidney diseases.

Key Group Insights for FSGS Stakeholders

ASEAN countries are strengthening nephrology networks while addressing heterogeneous access to kidney biopsy, chronic kidney disease screening, and immunosuppressive monitoring, making standardized FSGS diagnostic pathways a priority. In the GCC, investment in tertiary care, transplantation, and genomic medicine is increasing the ability to distinguish primary, secondary, and hereditary FSGS, particularly in settings where consanguinity and inherited renal disease are clinically relevant. The European Union supports FSGS advancement through coordinated rare disease policies, collaborative registries, clinical research harmonization, and guideline-driven nephrology practice that improves cross-country comparability of outcomes. BRICS economies combine large patient populations with rising chronic kidney disease burdens, expanding clinical research capacity, and major needs for accessible diagnostics, affordability, and early intervention; China, India, Brazil, Russia, and South Africa each contribute distinct epidemiologic and health-system considerations. G7 countries generally have mature nephrology infrastructure, stronger reimbursement pathways for advanced diagnostics, and high participation in global rare kidney disease studies, supporting evidence generation for FSGS care. NATO countries overlap substantially with high-income North American and European systems, where military and civilian health research infrastructures can support kidney disease surveillance, digital health integration, and multidisciplinary chronic disease management, although FSGS care remains primarily driven by national health policy and specialist nephrology capacity.

Key Country Insights in FSGS Care and Research

The United States is a leading center for FSGS clinical research, rare kidney disease registries, transplant nephrology, and APOL1-associated kidney disease investigation, while disparities in kidney outcomes among people of African ancestry remain a central policy and clinical concern. Canada combines universal health coverage with strong academic nephrology programs, though geography can affect access to specialized renal pathology and genetic counseling in remote areas. Mexico and Brazil face growing chronic kidney disease pressure and regional variability in access to biopsy, dialysis, transplantation, and specialist care, with Brazil maintaining significant nephrology and transplant expertise. The United Kingdom, Germany, France, Italy, and Spain benefit from established glomerular disease services, renal registries, biopsy-based diagnostics, and guideline-aligned management, while the United Kingdom and France also have strong rare disease coordination models. Russia has major nephrology capacity concentrated in urban centers, with access variability across its large geography. China is rapidly expanding nephrology research, renal pathology capacity, and chronic kidney disease programs, making it increasingly important in FSGS diagnosis and clinical study participation. India faces a high burden of chronic kidney disease drivers, including diabetes and hypertension, alongside expanding but uneven nephrology access, creating demand for cost-effective FSGS diagnostic and treatment algorithms. Japan has advanced nephrology infrastructure, widespread health screening practices, and strong biopsy-based kidney disease expertise, supporting early glomerular disease detection. Australia has robust kidney registries and transplant services, while Indigenous populations experience disproportionate kidney disease burden that shapes public health priorities. South Korea combines advanced medical technology, strong specialty care, and active chronic kidney disease management programs, supporting uptake of precision nephrology approaches.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated differentiation of FSGS subtypes, because primary, genetic, and secondary forms require different treatment strategies and trial designs. Investment should focus on renal pathology quality, access to electron microscopy where appropriate, genetic testing pathways, APOL1 risk assessment in relevant populations, and standardized proteinuria and kidney function monitoring. Clinical development teams should design studies that account for disease heterogeneity, background supportive therapy, baseline proteinuria, histologic chronicity, and patient-reported outcomes. Health systems should expand multidisciplinary care involving nephrologists, renal pathologists, genetic counselors, transplant specialists, dietitians, pharmacists, and primary care teams. Digital health leaders should implement validated AI tools cautiously, emphasizing explainability, bias assessment, data security, and clinician oversight. Policy stakeholders should improve equitable access to kidney biopsy, essential kidney-protective medicines, dialysis, transplantation, and rare disease referral networks. Patient engagement is also critical: education on proteinuria monitoring, blood pressure control, medication adherence, edema recognition, and clinical trial opportunities can improve continuity of care and shared decision-making.

Research Methodology

This executive summary is developed through secondary research grounded in publicly available and clinically recognized sources, including peer-reviewed nephrology literature, kidney disease guidelines, renal registry publications, transplant and chronic kidney disease datasets, rare disease research resources, and consensus statements from nephrology and pathology communities. The methodology emphasizes evidence triangulation across epidemiology, clinical practice, diagnostics, treatment pathways, regional healthcare infrastructure, and emerging technology trends. Findings are synthesized qualitatively to avoid unsupported market sizing, market share, or forecasting claims. Regional, group, and country insights are interpreted through the lenses of kidney disease burden, biopsy access, genetic testing availability, nephrology workforce maturity, transplant capacity, rare disease infrastructure, and health equity considerations. Because FSGS is a histologic pattern rather than a single uniform disease, the analysis prioritizes clinical-pathologic correlation, subtype distinction, and data-backed understanding of risk factors such as APOL1 high-risk genotypes, metabolic disease, hypertension, medication exposures, infections, and hereditary kidney disorders.

Conclusion

Focal segmental glomerulosclerosis remains a high-need kidney disease area defined by diagnostic complexity, heterogeneous causes, and meaningful risk of chronic kidney disease progression. The most important industry shift is the move toward precision nephrology: better subtype identification, improved pathology interpretation, broader use of genetic insights, and more disciplined selection of immunosuppressive or supportive treatment strategies. Artificial intelligence, digital pathology, and real-world data analytics can strengthen the FSGS ecosystem when validated responsibly and embedded into expert-led clinical workflows. Regional opportunities differ substantially, from advanced rare disease research networks in North America, Europe, Japan, South Korea, and Australia to expanding access priorities across Latin America, Africa, parts of Asia-Pacific, and the Middle East. For stakeholders across healthcare delivery, diagnostics, research, and policy, the path forward is clear: improve early recognition of proteinuria, expand equitable diagnostic access, stratify patients accurately, support clinical research participation, and align innovation with measurable kidney health outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Focal Segmental Glomerulosclerosis Market, by Drug Class

• 7.1. Introduction
• 7.2. Angiotensin Enzyme Inhibitors
• 7.3. Angiotensin Receptor Blockers
• 7.4. Corticosteroids

8. Focal Segmental Glomerulosclerosis Market, by Disease Type

• 8.1. Introduction
• 8.2. Primary Focal Segmental Glomerulosclerosis
• 8.3. Secondary Focal Segmental Glomerulosclerosis
  • 8.3.1. Virus-associated FSGS
  • 8.3.2. Drug-induced FSGS
  • 8.3.3. Hypertension-associated FSGS
• 8.4. Genetic FSGS
  • 8.4.1. Podocin Mutation-Related FSGS
  • 8.4.2. Alpha-Actinin-4 Mutation-Related FSGS

9. Focal Segmental Glomerulosclerosis Market, by Treatment Type

• 9.1. Introduction
• 9.2. Pharmacological Therapy
  • 9.2.1. Immunosuppressants
  • 9.2.2. Corticosteroids
• 9.3. Targeted Therapy
  • 9.3.1. SGLT2 Inhibitors
  • 9.3.2. Endothelin Receptor Antagonists
• 9.4. Supportive Therapy
• 9.5. Biologics
  • 9.5.1. Monoclonal
  • 9.5.2. RNA-Based

10. Focal Segmental Glomerulosclerosis Market, by Route Of Administration

• 10.1. Introduction
• 10.2. Oral
• 10.3. Injectable
• 10.4. Intravenous
• 10.5. Subcutaneous

11. Focal Segmental Glomerulosclerosis Market, by Patient Type

• 11.1. Introduction
• 11.2. Pediatric
• 11.3. Adult
• 11.4. Geriatric

12. Focal Segmental Glomerulosclerosis Market, by End User

• 12.1. Introduction
• 12.2. Hospitals
• 12.3. Specialty Clinics
• 12.4. Dialysis Centers
• 12.5. Ambulatory Surgical Centers
• 12.6. Homecare Settings
• 12.7. Academic & Research Institutes

13. Focal Segmental Glomerulosclerosis Market, by Distribution Channel

• 13.1. Introduction
• 13.2. Offline
• 13.3. Online

14. Focal Segmental Glomerulosclerosis Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Focal Segmental Glomerulosclerosis Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Focal Segmental Glomerulosclerosis Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2025
• 17.2. FPNV Positioning Matrix, 2025
• 17.3. Market Concentration Analysis, 2025
  • 17.3.1. Concentration Ratio (CR)
  • 17.3.2. Herfindahl Hirschman Index (HHI)
• 17.4. Recent Developments & Impact Analysis, 2025
• 17.5. Product Portfolio Analysis, 2025
• 17.6. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Aldeyra Therapeutics, Inc.
• 18.2. Amgen Inc.
• 18.3. Astellas Pharma Inc.
• 18.4. Aurinia Pharmaceuticals Inc.
• 18.5. Bayer AG
• 18.6. Boehringer Ingelheim International GmbH
• 18.7. Bristol-Myers Squibb Company
• 18.8. CSL Limited
• 18.9. Dimerix Limited
• 18.10. Eli Lilly and Company
• 18.11. F. Hoffmann-La Roche Ltd
• 18.12. Gilead Sciences, Inc.
• 18.13. GSK plc
• 18.14. Ionis Pharmaceuticals, Inc.
• 18.15. Johnson & Johnson
• 18.16. Merck & Co., Inc.
• 18.17. Novartis AG
• 18.18. Omeros Corporation
• 18.19. Otsuka Pharmaceutical Co., Ltd.
• 18.20. Pfizer Inc.
• 18.21. Sanofi SA
• 18.22. Takeda Pharmaceutical Company Limited
• 18.23. Travere Therapeutics, Inc.
• 18.24. Vertex Pharmaceuticals Incorporated
• 18.25. ZyVersa Therapeutics, Inc.